title: Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.
abstract: Clinical trials of oncolytic virotherapy have shown low toxicity and encouraging signs of efficacy. However, it remains critically important to develop methods for systemic viral delivery if such therapies are to be clinically implemented to treat established tumors. In this respect, much effort is being focused on combining oncolytic viruses with standard treatment modalities such as inhibitors of VEGF165 (an alternatively spliced isoform of VEGF-A) signaling, which are widely used to treat several different cancers. Here, we have demonstrated that combining VEGF165 inhibitors with systemic delivery of oncolytic viruses leads to substantial regression and cure of established tumors in immunocompetent mice. We have shown that manipulating VEGF165-mediated signaling by administering VEGF165 to mice harboring mouse melanoma cells that do not express VEGF165 and by administering a VEGF inhibitor and then withdrawing treatment to allow VEGF levels to rebound in mice harboring mouse melanoma cells expressing VEGF165 allows tumor-associated endothelial cells transiently to support viral replication. This approach led to direct tumor cell lysis and triggered innate immune-mediated attack on the tumor vasculature. It also resulted in long-term antitumor effects, even against tumors in which viral replication is poorly supported. Since this combinatorial approach targets the tumor endothelium, we believe these data have direct, wide-ranging, and immediate clinical applicability across a broad range of tumor types.
authors.affiliation: Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: Timothy
authors.initials: T
authors.lastname: Kottke
authors.forename: Geoff
authors.initials: G
authors.lastname: Hall
authors.forename: Jose
authors.initials: J
authors.lastname: Pulido
authors.forename: Rosa Maria
authors.initials: RM
authors.lastname: Diaz
authors.forename: Jill
authors.initials: J
authors.lastname: Thompson
authors.forename: Heung
authors.initials: H
authors.lastname: Chong
authors.forename: Peter
authors.initials: P
authors.lastname: Selby
authors.forename: Matt
authors.initials: M
authors.lastname: Coffey
authors.forename: Hardev
authors.initials: H
authors.lastname: Pandha
authors.forename: John
authors.initials: J
authors.lastname: Chester
authors.forename: Alan
authors.initials: A
authors.lastname: Melcher
authors.forename: Kevin
authors.initials: K
authors.lastname: Harrington
authors.forename: Richard
authors.initials: R
authors.lastname: Vile
mesh_terms: D017398:Alternative Splicing; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D042783:Endothelial Cells / Q000166:cytology; D007107:Immune System; D008546:Melanoma, Experimental / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008954:Models, Biological; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000628:therapy*; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000378:metabolism; D020033:Protein Isoforms; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D020033:Protein Isoforms; D042461:Vascular Endothelial Growth Factor A; C467480:vascular endothelial growth factor A, mouse